Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma (BBIO) Form 144 filing: The filing notifies a proposed sale of 17,353 shares of common stock through Morgan Stanley Smith Barney LLC on 08/18/2025 with an aggregate market value of $871,722.75. The filing reports 191,168,504 shares outstanding. The shares to be sold were issued as restricted stock in four grants: 4,757 shares acquired 11/16/2023, 3,048 shares acquired 08/16/2023, 6,264 shares acquired 02/16/2024, and 3,284 shares acquired 05/16/2024. The filer reports nothing to report for securities sold in the past three months and affirms they do not possess undisclosed material adverse information.
Amendment No. 8 to a Schedule 13D reports updated beneficial ownership information for the common stock of BridgeBio Pharma, Inc. ("Common Stock"). Multiple Viking-related entities and individuals are disclosed as reporting persons. Percentage calculations are based on 191,168,504 shares outstanding as of July 29, 2025. The cover pages show key positions: Viking Global Investors LP reports shared beneficial ownership of 17,780,183 shares (9.3%); Viking Global Opportunities-related entities report shared holdings of 17,489,651 shares (9.1%); and three individuals (O. Andreas Halvorsen, David C. Ott and Rose S. Shabet) are each reported with shared beneficial ownership of 18,602,920 shares (9.7%). The filing states the funds used were investor capital and incorporates a Schedule of Transactions as Exhibit 99.8. No transactions since Amendment No. 7 are reported except those listed in Exhibit 99.8.
BridgeBio Pharma director Charles J. Homcy executed pre-planned stock sales under a Rule 10b5-1 plan, selling a total of 300,000 shares of BBIO across transactions dated 08/08/2025 and 08/11/2025. The filings show sales of 191,662 shares at a weighted average price near $45.87, 58,338 shares at a weighted average near $46.64, and 50,000 shares at $48, leaving the reporting person with 916,674 shares following the final sale.
The disclosure notes the transactions were effected under a 10b5-1 plan adopted May 8, 2025, and the reporter remains a significant holder with well over nine hundred thousand shares. All sales are reported as direct holdings without derivative activity disclosed.
BridgeBio Pharma (BBIO) Form 4 filed by Maricel Apuli, Chief Accounting Officer, reports a sale on 08/07/2025 of 1,000 shares of common stock at $45.44 per share. After the transaction, Apuli directly beneficially owned 141,859 shares. The form was signed on 08/11/2025. No derivative transactions were reported.
BridgeBio Pharma CEO and director Kumar Neil reported the sale of common stock on August 7–8, 2025. The Form 4 discloses total dispositions of 217,404 shares, and notes the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.
Footnotes disclose weighted average sale price ranges of approximately $44.31–$47.20 per share across the transactions. The filing lists indirect beneficial ownership following the reported transactions, including holdings of 4,718,447 and 915,686 shares via two trusts, and is signed by an attorney-in-fact on August 11, 2025.
BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000. The filing shows 191,168,504 shares outstanding.
The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer and paid for in cash. The filing also discloses three sales by Charles J Homcy on 08/08/2025 totaling 250,000 common shares with gross proceeds of $6,907,905, $2,302,295 and $2,302,220 (combined $11,512,420).
BridgeBio Pharma, Inc. (BBIO) filed a Form 144 disclosing a proposed sale of 250,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $11,512,420.00 and total shares outstanding reported as 191,168,504. The securities were acquired as founder shares on 07/01/2019 from the issuer and payment was recorded on that date. The filing reports no securities sold during the past three months. The notice includes the required representation about no undisclosed material adverse information. The document does not provide identifying filer contact details or a listed plan adoption date for any Rule 10b5-1 trading plan.